Health Technology Nichi-Iko Pharmaceutical Co., Ltd. Business Summary
Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.
Financial Highlights
Mar 2022
JPY USD Revenue 179,060M 1,593.44M Gross Profit 3,975M 35.37M Operating income -28,152M -250.52M Income before tax -107,964M -960.76M Net income -104,875M -933.27M EBITDA -15,499M -137.92M Diluted EPS -1,552.73 -13.81 Dividends Per Share -- -- Total Assets 260,672M 2,147.65M Total liabilities 246,753M 2,032.98M Total equity 13,536M 111.52M Operating cash flow -24,248M -215.78M Currency in JPY Currency in USD
Historical Data Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
164,717M
166,592M
190,076M
188,218M
179,060M
Gross Profit
40,803M
33,158M
37,320M
21,245M
3,975M
Operating income
13,200M
7,221M
7,572M
-9,867M
-28,152M
Income before tax
9,067M
8,903M
7,396M
636M
-107,964M
Net income
8,069M
6,864M
5,133M
-4,180M
-104,875M
EBITDA
22,179M
16,987M
19,443M
3,350M
-15,499M
Diluted EPS
142.92
114.03
80.12
-65.27
-1,552.73
Dividends Per Share
30
30
30
25
--
Total Assets
278,364M
306,838M
336,819M
363,572M
260,672M
Total liabilities
190,819M
190,511M
219,644M
251,134M
246,753M
Total equity
87,542M
116,323M
115,827M
111,167M
13,536M
Operating cash flow
18,925M
23,811M
18,450M
5,006M
-24,248M
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
1,486.18M
1,502.25M
1,748.21M
1,774.68M
1,593.44M
Gross Profit
368.15M
299.00M
343.24M
200.31M
35.37M
Operating income
119.09M
65.11M
69.64M
-93.03M
-250.52M
Income before tax
81.80M
80.28M
68.02M
5.99M
-960.76M
Net income
72.80M
61.89M
47.21M
-39.41M
-933.27M
EBITDA
200.11M
153.18M
178.82M
31.58M
-137.92M
Diluted EPS
1.28
1.02
0.73
-0.61
-13.81
Dividends Per Share
0.27
0.27
0.27
0.23
--
Total Assets
2,617.43M
2,772.17M
3,119.99M
3,290.24M
2,147.65M
Total liabilities
1,794.25M
1,721.19M
2,034.58M
2,272.70M
2,032.98M
Total equity
823.14M
1,050.93M
1,072.91M
1,006.03M
111.52M
Operating cash flow
170.75M
214.71M
169.69M
47.20M
-215.78M
Valuation Measures
Mar 2022
PER -- ROA -33.60% ROE -168.19% Operating margin -15.72% Profit margin -58.56%
Key executives
President & Representative Director:
Yuichi Tamura
Finance Manager:
Naoyuki Okada
Head-Compliance Management & Guidance:
Yasutomo Sai
Director, VP, Head-CSR, ESG & Business Creation:
Kenji Akane
Executive Officer & Personnel Manager:
Keiichi Arakawa Shareholders
TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (11.8%)
Medipal Holdings Corp. (9.7%)
Hokuhoku Financial Group, Inc. (3.9%)
Nomura Asset Management Co., Ltd. (2.6%)
Dimensional Fund Advisors LP (2.2%)
The Vanguard Group, Inc. (1.9%)
Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.5%)
Nichi-Iko Pharmaceutical Co., Ltd. (1.3%)
Nikko Asset Management Co., Ltd. (1.2%)
Daiwa Asset Management Co. Ltd. (1.2%)
Related Companies
Nichi Iko Business Association
Nichi Iko Pharmaceutical Co. /Toyama Daini Kojo/
Nichi-Iko Gifu Plant Co., Ltd.
Nichi-Iko Pharma Tech Co., Ltd.
Elmed Co., Ltd.
Nichi Iko Pharmaceutical Trust
SterRx LLC
Nichi-Iko Pharmaceutical Employee Incentive Plan
Nichiiko Pharma KK
Nichiiko Osaka KK
Yakuhan Pharmaceutical Co., Ltd.
Sagent Pharmaceuticals, Inc.
Kobayashi Pharmaceutical Industries Co. Ltd.
Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
Oriental Pharmaceutical Co., Ltd.
Teikoku Medix Co., Ltd.
Japan Galen, Inc.
Maruko Pharmaceutical Co. Ltd.
Nichiiko Pharmaceutical Employee Stock Pwnership Plan
Competitors
Dr. Reddy's Laboratories Ltd.
Cumberland Pharmaceuticals Inc.
Amphastar Pharmaceuticals, Inc.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Jun, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close